The partnership marks a strategic step to strengthen Indonesia’s health resilience by reducing dependence on imports and enhancing self-sufficiency in healthcare services.
Danantara Indonesia’s Chief Investment Officer, Pandu Sjahrir, said that one of Danantara’s key investment focuses is reinforcing national resilience in critical sectors, including healthcare.
He noted that the collaboration between SK Plasma’s technical expertise and Danantara’s investment aims to improve patient care quality and contribute to saving lives through innovative, globally standardized therapies.
Pandu emphasized that the signing of this MoU represents an important milestone in building a healthier and stronger Indonesia.
In line with its 2025 investment strategy, Danantara has designated healthcare as one of its eight priority sectors, including the development of blood plasma facilities and national health infrastructure.
SK Plasma CEO Kim Seung-joo expressed his appreciation for the collaboration, describing it as an honor for SK Plasma to contribute to strengthening Indonesia’s healthcare system.
Leveraging its expertise in producing plasma-derived medicinal products (PDMP), SK Plasma is committed to working closely with countries seeking to localize essential medicines while contributing to the improvement of global healthcare infrastructure.
SK Plasma is a global leader in the production of PDMPs, which are vital therapies for patients with rare or critical conditions.
The partnership with Danantara is expected to advance Indonesia’s efforts toward self-sufficiency in plasma-derived medicines while creating new job opportunities for skilled professionals in biotechnology and pharmaceuticals.
The company also pledged to support knowledge transfer through training programs for Indonesian workers at its facilities in South Korea.
PDMPs are pharmaceutical products made from human plasma through a process known as fractionation. These therapies play a crucial role in treating serious, often life-threatening diseases for which patients have few effective alternatives.
Until now, Indonesia has relied entirely on imports to meet its PDMP needs, making the supply vulnerable to global disruptions.
To address this, Danantara and SK Plasma plan to strengthen local manufacturing capabilities by building a plasma derivative production facility in Karawang, West Java, which is expected to be completed by 2026.
Danantara believes that a robust and independent healthcare system can drive national economic growth, as investment in this sector not only boosts productivity but also reduces healthcare costs for millions of people.
Over the next year, Danantara will focus on three key areas within healthcare, namely services, manufacturing, and innovation.
Through its subsidiary PT SK Plasma Core Indonesia, SK Plasma is currently constructing a plasma fractionation facility that will enable Indonesia to locally produce PDMPs.
This initiative is expected to not only lessen import dependence but also accelerate technology transfer and the development of a highly skilled workforce.
Following the signing, both parties will continue exploring further investment opportunities and will announce details in due course, following due diligence and compliance with applicable legal regulations.
Related news: Indonesia calls for global collaboration on health resilience
Related news: RI reaffirms global financial health to boost community resilience
Related news: Local production of blood bags to strengthen health system: Minister
Translator: Primayanti
Editor: Azis Kurmala
Copyright © ANTARA 2025
